

MELAN ACCRUAL REPORT - Open and Recently Closed Studies

SWOG/ Support	STUDY	O R P E E G N	ARM	ACCR. GOAL	TOTAL REGS.	REGS.	REGS.	REGS.	REGS.	REGS.	DATE OF FIRST REG.	# of ACT. INSTs	# of CURR IRBs	
						LAST 12 Month	LAST 6 Month	LAST 3 Month	LAST 30 DAYS	LAST 7 DAYS				
SWOG	S1320-Adv, BRAF mut, Inter v Contin	1	Y 1	Lead-in Continuous Dosing	280	218	62	29	12	3	0	09/19/2014	229	106
						218	62	29	12	3	0			
		2	Y 2	Continuous Dosing	280	91	29	16	7	2	1	09/19/2014		
				3 Intermittent Dosing		87	25	14	8	1	0			
						178	54	30	15	3	1			
	S1512-Melan, Adv, Desmoplastic, MK-3475 (pembro)	1	Y 1	MK-3475 (pembrolizumab)	77	11	10	7	5	1	1	02/06/2017	75	39
						11	10	7	5	1	1			
	S1607-MELAN, Adv, T-VEC, MK-3475	1	Y 1	T-VEC + MK-3475(pembrolizumab)	64	1	1	1	1	1	0	06/05/2018		19
						1	1	1	1	1	0			
	S1616-MELAN, Adv, Ipilimumab ± Nivolumab	1	Y 1	Ipilimumab	94	4	4	3	2	1	0	10/23/2017		93
				2 Nivolumab + Ipilimumab		10	10	8	4	3	0			
						14	14	11	6	4	0			
Yes	EA6134-Adv, BRAF mut, D+T/Ipi+Niv vs Ipi+Niv/D+T	1	E	Total Registrations		26	10	2	1	0	0	11/03/2015	346	147
						26	10	2	1	0	0			
		2	E	Total Registrations		7	4	2	0	0	0	11/03/2015		
						7	4	2	0	0	0			
	EA6141-Melan, Avd, Nivolumab+Ipi ± Sargmostim	1	E	Total Registrations		36	4	0	0	0	0	03/25/2016	301	120
						36	4	0	0	0	0			